欢迎来到范德生物BIOFOUNT
范德生物中国

中文范德生物中文语言

范德生物产品购买购物车
0
搜索
Desferrithiocin_105635-60-6_产品详情
105635-60-6
  • names:

    (S)-4,5-Dihydro-2-(3-hydroxy-2-pyridinyl)-4-methyl-4-thiazolecarboxylic acid monosodium salt

  • CAS号:

    105635-60-6

    MDL Number:
  • MF(分子式): C10H9N2NaO3S MW(分子量): 260.24
  • EINECS: Reaxys Number:
  • Pubchem ID: Brand:BIOFOUNT
Desferrithiocin
货品编码 规格 纯度 价格 (¥) 现价(¥) 特价(¥) 库存描述 数量 总计 (¥)
快速询价
收起
你想询价的产品
请准确填写您的联系方式,以便为您提供最好的服务。
中文别名 Desferrithiocin
英文别名 Desferrithiocin; DFT;
CAS号 105635-60-6
Inchi InChI=1S/C10H10N2O3S.Na/c1-10(9(14)15)5-16-8(12-10)7-6(13)3-2-4-11-7;/h2-4,13H,5H2,1H3,(H,14,15);/q;+1/p-1/t10-;/m1./s1
InchiKey UGJSEILLHZKUBG-HNCPQSOCSA-M
分子式 Formula C10H9N2NaO3S
分子量 Molecular Weight 260.24
溶解度Solubility
性状 Solid powder
储藏条件 Storage conditions Dry, dark and store at 0-4℃ for short term (days to weeks) or -20℃ for long term (Store correctly 2-3years).
产品说明 Desferrithiocin(CAS:105635-60-6):仅限应用于工业或者科学研究过程中非医疗目的,不应用于人类或动物的临床诊断以及治过程疗,该产品非药用,非食用。
IntroductionDesferrithiocin is an orally effective Fe chelator that is more active than desferrioxamine.
Application1
Application2
Application3
警示图
危险性 Warning
危险性警示
安全声明
安全防护
备注
[1]Taher AT, Saliba AN, Kuo KH, Giardina PJ, Cohen AR, Neufeld EJ, Aydinok Y, Kwiatkowski JL, Jeglinski BI, Pietropaolo K, Berk G, Viprakasit V. Safety and pharmacokinetics of the oral iron chelator SP-420 in β-thalassemia. Am J Hematol. 2017 Dec;92(12):1356-136[1]doi: 10.1002/ajh.24914. Epub 2017 Oct 3[1]PubMed PMID: 28940308.
[2]Kaviani S, Izadyar M, Housaindokht MR. A DFT study on the complex formation between desferrithiocin and metal ions (Mg(2+), Al(3+), Ca(2+), Mn(2+), Fe(3+), Co(2+), Ni(2+), Cu(2+), Zn(2+)). Comput Biol Chem. 2017 Apr;67:114-121. doi: 10.1016/j.compbiolchem.2016.12.012. Epub 2017 Jan 3. PubMed PMID: 28068516.
[3] Bergeron RJ, Bharti N, McManis JS, Wiegand J. Metabolically programmed iron chelators. Bioorg Med Chem. 2015 Sep 1;23(17):5954-71. doi: 10.1016/j.bmc.2015.06.059. Epub 2015 Jun 29. PubMed PMID: 26231739; PubMed Central PMCID: PMC4608554.
[4] Hider RC, Kong X, Abbate V, Harland R, Conlon K, Luker T. Deferitazole, a new orally active iron chelator. Dalton Trans. 2015 Mar 21;44(11):5197-204. doi: 10.1039/c5dt00063g. PubMed PMID: 25687725.
[5] Bergeron RJ, Wiegand J, McManis JS, Bharti N. Desferrithiocin: a search for clinically effective iron chelators. J Med Chem. 2014 Nov 26;57(22):9259-91. doi: 10.1021/jm500828f. Epub 2014 Sep 10. Review. PubMed PMID: 25207964; PubMed Central PMCID: PMC4255733.
6: Bergeron RJ, Wiegand J, Bharti N, McManis JS. Substituent effects on desferrithiocin and desferrithiocin analogue iron-clearing and toxicity profiles. J Med Chem. 2012 Aug 23;55(16):7090-103. doi: 10.1021/jm300509y. Epub 2012 Aug 13. PubMed PMID: 22889170; PubMed Central PMCID: PMC3583384.7: Bergeron RJ, Wiegand J, Bharti N, McManis JS, Singh S. Desferrithiocin analogue iron chelators: iron clearing efficiency, tissue distribution, and renal toxicity. Biometals. 2011 Apr;24(2):239-58. doi: 10.1007/s10534-010-9389-y. Epub 2010 Nov 20. PubMed PMID: 21103911; PubMed Central PMCID: PMC3329216.8: Bergeron RJ, Bharti N, Wiegand J, McManis JS, Singh S, Abboud KA. The impact of polyether chain length on the iron clearing efficiency and physiochemical properties of desferrithiocin analogues. J Med Chem. 2010 Apr 8;53(7):2843-53. doi: 10.1021/jm9018146. PubMed PMID: 20232803; PubMed Central PMCID: PMC2951135.9: Bergeron RJ, Wiegand J, Singh S. Desferrithiocin analogue uranium decorporation agents. Int J Radiat Biol. 2009 Apr;85(4):348-61. doi: 10.1080/09553000902781089. PubMed PMID: 19399680; PubMed Central PMCID: PMC2861555.10: Bergeron RJ, Wiegand J, McManis JS, Bharti N, Singh S. Desferrithiocin analogues and nephrotoxicity. J Med Chem. 2008 Oct 9;51(19):5993-6004. doi: 10.1021/jm8003398. Epub 2008 Sep 13. PubMed PMID: 18788724; PubMed Central PMCID: PMC2778308.1
    对不起,暂无产品评价!
MSDS
SDS 1.0 中文
展开
SDS 1.0 英文
展开
        新闻
        抱歉,暂无数据!
        My title page contents